Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...

Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...

Zimmer Biomet also recently received US regulatory approval of its Oxford partial cementless knee. While Oxford has been a dominant competitor in the partial knee category, the cementless version ...

When shares of Zimmer Biomet (NYSE:ZBH) moved down to the $105 mark in September, I believed that real value was showing up. Shares sold off despite the projection of mid-single digit sales growth ...